Precision NanoSystems, a provider of innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research, was featured in an article published in the June 2012 edition of the journal Nature Biotechnology. The article titled “Proof of concept for next-generation nanoparticle drugs in humans” assessed the current status of nanoparticle drug development with a focus on the next-generation of nanoparticle drugs undergoing clinical development. Precision’s technology was highlighted as a new manufacturing approach that enables controlled, “bottom-up” preparation of therapeutic lipid nanoparticle systems.
Precision NanoSystems CEO James Taylor, Ph.D. commented, “This article is great exposure for an early-stage company like Precision. It highlights the unique characteristics of the microfluidics-based manufacturing platform that we believe will enable the expanded development of next-generation nanoparticle drugs”
About Precision NanoSystems, Inc.
At Precision NanoSystems we are creating innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research. Our proprietary NanoAssemblr platform enables the simple, rapid, reproducible, and scalable manufacture of next-generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to difficult-to-access cells and tissues in the body. We provide instruments, reagents and services to life sciences researchers and build strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.